The SynCardia total artificial heart (TAH), a pneumatically driven biventricular replacement pump used mainly as a bridge to transplantation, requires lifelong antithrombotic therapy whose optimal regimen is undefined. Copeland and colleagues (ASAIO Journal, 2013) reported a 15-year, 99-patient single-center series managed with thromboelastography- and platelet-aggregation-guided heparin plus dipyridamole, pentoxifylline, and aspirin, observing an embolic stroke rate of 0.08 events per patient-year, no spontaneous hemorrhagic strokes, and no heparin-induced thrombocytopenia (HIT), while acknowledging that the protocol had never been compared with warfarin/aspirin-centered strategies, that HIT risk was assessed without systematic PF4-heparin antibody surveillance, that generalizability to other centers was unproven, and that the acquired hemostatic changes underlying the observed coagulation trajectory were uncharacterized. The question remains open: no prospective or controlled comparison of antithrombotic strategies in TAH recipients is known to date, and the studies that have followed the source report are single-center observational series, case reports, or monitoring-method agreement studies.

Background

A total artificial heart (TAH) is a mechanical pump that replaces both native ventricles and all four valves; it is implanted in patients with irreversible biventricular heart failure, most often as a bridge to heart transplantation. The only TAH in widespread clinical use is the SynCardia TAH (Tucson, AZ, USA), a pneumatically driven pulsatile device with mechanical valves and polyurethane blood-contacting surfaces, which has been implanted in over 2,000 patients worldwide. Because all blood-contacting surfaces of the device are thrombogenic, recipients need intensive antithrombotic therapy; paradoxically, the same therapy and the device-induced hemostatic alterations also predispose these patients to bleeding. Balancing thrombosis against hemorrhage is therefore the central pharmacologic problem of TAH support, and it is managed with markedly different regimens across implanting centers.

Several specialist terms are needed. Thromboelastography (TEG) is a viscoelastic point-of-care assay that traces clot formation and lysis in whole blood and can also quantify platelet inhibition (platelet mapping), allowing individualized titration of anticoagulant and antiplatelet drugs. Unfractionated heparin infusions are conventionally monitored with the activated partial thromboplastin time (aPTT), which is increasingly replaced by the chromogenic anti-factor Xa assay that directly measures heparin concentration; the two assays are known to disagree frequently in critically ill patients. HIT (heparin-induced thrombocytopenia) is a prothrombotic immune reaction to complexes of heparin and platelet factor 4 (PF4), detected by PF4-heparin antibody serology; HIT with thrombosis (HITT) is its severe form. Acquired von Willebrand syndrome (AVWS) is a loss of the largest (highest-molecular-weight) multimers of von Willebrand factor (vWF) caused by high shear stress or device surfaces, which impairs platelet adhesion and promotes mucosal bleeding; it is well documented after continuous-flow left ventricular assist devices (LVADs). INTERMACS profiles grade illness severity at implantation, with profile 1 denoting the most critically ill patients.

In the source study, Copeland, Copeland, Nolan, Gustafson, Slepian, and Smith (ASAIO Journal, 2013) reported 99 consecutive SynCardia TAH recipients managed over 15 years at a single center (Tucson/University of California San Diego program) with a consistent protocol: TEG and platelet aggregation studies guided therapy with dipyridamole, pentoxifylline, aspirin, and heparin, supplemented by aPTT, INR, and platelet counts. Among the 97 patients free of endo-device infection, embolic stroke incidence was 0.08 per patient-year over 23.6 patient-years of support, no spontaneous hemorrhagic strokes occurred, postimplantation bleeding occurred in 20%, and HIT was not observed in any patient. The authors recommended their protocol, but the limitations they acknowledged define the unresolved question: the result is a single-center, uncontrolled observation. Other major programs use different regimens — for example the Mayo Clinic multi-targeted guideline based on kaolin and heparinase TEG with platelet light-transmission aggregometry (Ramirez, Riley, and Joyce, 2016), the Harefield program's heparin-to-warfarin transition (Monteagudo-Vela and colleagues, 2022), and anti-Xa-based heparin monitoring — and there is no TAH-specific antithrombotic guideline or consensus statement. Later single-center series report neurological event rates far above the Tucson figures (for example 4.6 ischemic strokes per 100 patient-months at Cedars-Sinai, and neurological events in 39.3% of 196 Bad Oeynhausen patients), and pooled analyses of TAH studies report stroke rates near 11% and postoperative bleeding near 42%, although patient acuity, era, and protocol differences confound these comparisons. The mechanisms linking inflammation, the postimplant rise in platelet count and fibrinogen, vWF multimer loss, and device thrombogenicity under each regimen are only beginning to be characterized (Reich and colleagues, 2017, provided the first TAH vWF profiling). Whether dipyridamole — routinely used in the Tucson protocol — modulates HIT risk was never tested, since no systematic PF4-heparin antibody surveillance was performed.

Problem Statement

Establish, with prospective comparative (ideally multicenter) evidence, the optimal antithrombotic management of SynCardia total artificial heart recipients. Specifically: (1) determine whether the thromboelastography- and platelet-aggregation-guided heparin-plus-antiplatelet regimen (dipyridamole, pentoxifylline, aspirin, heparin) of Copeland et al. (2013) and the warfarin/aspirin-centered strategies used at other major programs differ in clinically adjudicated thromboembolic outcomes (embolic stroke, device thrombosis) and hemorrhagic outcomes (spontaneous hemorrhagic stroke, postimplantation and gastrointestinal bleeding) — including whether viscoelastic-guided regimens that use lower heparin infusion rates (if any) reduce hemorrhagic complications without increasing thromboembolic events; (2) establish whether the very low embolic-stroke rate (0.08 events per patient-year) and absence of heparin-induced thrombocytopenia observed in the 99-patient single-center series generalize across centers, patient acuity mixes, and management practices (including centers that do not perform daily thromboelastography, use kaolin-activated TEG variants, or monitor heparin with anti-factor Xa rather than aPTT); (3) define the surveillance required, in particular whether routine prospective PF4-heparin antibody testing is needed to determine heparin-induced thrombocytopenia risk and whether dipyridamole materially reduces its incidence or severity in this population; and (4) characterize the acquired hemostatic changes — serial platelet count and fibrinogen dynamics and von Willebrand factor multimer profiles — that connect inflammation, device thrombogenicity, and bleeding under each regimen, so that the chosen strategy is supported by a mechanistic account of the postimplant coagulation trajectory.

All four parts of the Problem Statement are jointly required to resolve the task; answering only a subset does not constitute a complete resolution. A complete answer resolves each part as far as the existing evidence permits and specifies the prospective comparative study that would settle whatever remains unresolved.

References

  1. Copeland J, Copeland H, Nolan P, Gustafson M, Slepian M, Smith R. Results with an anticoagulation protocol in 99 SynCardia total artificial heart recipients. ASAIO Journal 2013;59(3):216-220. doi:10.1097/MAT.0b013e318288a390. https://pubmed.ncbi.nlm.nih.gov/23644607/
  2. Ramirez A, Riley JB, Joyce LD. Multi-targeted antithrombotic therapy for total artificial heart device patients. Journal of ExtraCorporeal Technology 2016;48(1):27-34. https://pubmed.ncbi.nlm.nih.gov/27134306/
  3. Monteagudo-Vela M, Bowles C, Raj B, Robinson D, Simon A. Anticoagulation in SynCardia total artificial heart recipients: anti-factor Xa or activated partial thromboplastin time? Interactive Cardiovascular and Thoracic Surgery 2022;34(2):322-325. doi:10.1093/icvts/ivab251. https://pubmed.ncbi.nlm.nih.gov/34849924/
  4. Reich HJ, Morgan J, Arabia F, Czer L, Moriguchi J, Ramzy D, Esmailian F, Lam L, Dunhill J, Volod O. Comparative analysis of von Willebrand factor profiles after implantation of left ventricular assist device and total artificial heart. Journal of Thrombosis and Haemostasis 2017;15(8):1620-1624. doi:10.1111/jth.13753. https://pubmed.ncbi.nlm.nih.gov/28586149/
  5. Volod O, Lam LD, Lin G, Kam C, Kolyouthapong K, Mac J, Mirocha J, Ambrose PJ, Czer LS, Arabia FA. Role of thromboelastography platelet mapping and international normalized ratio in defining 'normocoagulability' during anticoagulation for mechanical circulatory support devices: a pilot retrospective study. ASAIO Journal 2017;63(1):24-31. doi:10.1097/MAT.0000000000000445. https://pubmed.ncbi.nlm.nih.gov/27660902/
  6. Federman M, Dragomer D, Grant S, Reemtsen B, Biniwale R. Use of bivalirudin for anticoagulation during implantation of total artificial heart. Journal of ExtraCorporeal Technology 2014;46(2):170-172. https://pubmed.ncbi.nlm.nih.gov/25208436/
  7. Cios TJ, Salamanca-Padilla Y, Guvakov D. An anti-coagulation conundrum: implantation of total artificial heart in a patient with heparin-induced thrombocytopenia type II. American Journal of Case Reports 2017;18:294-298. doi:10.12659/AJCR.902320. https://pubmed.ncbi.nlm.nih.gov/28331172/
  8. Moledina S, Shanmuganathan M, Pathak S, Simon A. Spontaneous subdural haematoma in a patient with a total artificial heart on warfarin. BMJ Case Reports 2019;12(9):e230519. doi:10.1136/bcr-2019-230519. https://pubmed.ncbi.nlm.nih.gov/31488446/
  9. Torregrossa G, Morshuis M, Varghese R, Hosseinian L, Vida V, Tarzia V, Loforte A, Duveau D, Arabia F, Leprince P, Kasirajan V, Beyersdorf F, Musumeci F, Hetzer R, Krabatsch T, Gummert J, Copeland J, Gerosa G. Results with SynCardia total artificial heart beyond 1 year. ASAIO Journal 2014;60(6):626-634. doi:10.1097/MAT.0000000000000132. https://pubmed.ncbi.nlm.nih.gov/25158888/
  10. Maynes EJ, O'Malley TJ, Luc JGY, Weber MP, Horan DP, Choi JH, Patel S, Abbas Rizvi SS, Morris RJ, Entwistle JW, Massey HT, Tchantchaleishvili V. Comparison of SynCardia total artificial heart and HeartWare HVAD biventricular support for management of biventricular heart failure: a systematic review and meta-analysis. Annals of Cardiothoracic Surgery 2020;9(2):69-80. doi:10.21037/acs.2020.03.07. https://pubmed.ncbi.nlm.nih.gov/32309154/
  11. Tan MC, Yeo YH, Tham JW, Tan JL, Fong HK, Tan BE, Lee KS, Lee JZ. Adverse events in total artificial heart for end-stage heart failure: insight from the Food and Drug Administration Manufacturer and User Facility Device Experience (MAUDE). International Journal of Heart Failure 2024;6(2):76-81. doi:10.36628/ijhf.2023.0020. https://pubmed.ncbi.nlm.nih.gov/38694934/
  12. Malas J, Chen Q, Akhmerov A, Tremblay LP, Egorova N, Krishnan A, Moriguchi J, Kobashigawa J, Czer L, Cole R, Emerson D, Chikwe J, Arabia F, Esmailian F. Experience with SynCardia total artificial heart as a bridge to transplantation in 100 patients. Annals of Thoracic Surgery 2023;115(3):725-732. doi:10.1016/j.athoracsur.2022.11.034. https://pubmed.ncbi.nlm.nih.gov/36521527/
  13. Razumov A, Burri M, Zittermann A, Radakovic D, Lauenroth V, Rojas SV, Fox H, Schramm R, Gummert J, Deutsch MA, Morshuis M. Outcomes after SynCardia temporary total artificial heart implantation: a 20-year single-center experience in 196 patients. Artificial Organs 2025;49(2):266-275. doi:10.1111/aor.14860. https://pubmed.ncbi.nlm.nih.gov/39283166/
  14. Itagaki S, Toyoda N, Egorova N, Sun E, Lee T, Boateng P, Gibson G, Moss N, Mancini D, Adams DH, Anyanwu AC. Total artificial heart implantation as a bridge to transplantation in the United States. Journal of Thoracic and Cardiovascular Surgery 2024;167(1):205-214.e5. doi:10.1016/j.jtcvs.2022.02.058. https://pubmed.ncbi.nlm.nih.gov/35618532/
  15. Li S, Li A, Beckman JA, Kim C, Granich MA, Mondin J, Sabath DE, Garcia DA, Mahr C. Discordance between aPTT and anti-Xa in monitoring heparin anticoagulation in mechanical circulatory support. ESC Heart Failure 2024;11(5):2742-2748. doi:10.1002/ehf2.14816. https://pubmed.ncbi.nlm.nih.gov/38725133/
  16. Volod O, Colon MJ, Arabia FA. In search of the Holy Grail of artificial hearts: are we there yet? Seminars in Thrombosis and Hemostasis 2024;50(1):104-114. doi:10.1055/s-0043-1772456. https://pubmed.ncbi.nlm.nih.gov/37604198/
  17. Sunagawa G, Horvath DJ, Karimov JH, Moazami N, Fukamachi K. Future prospects for the total artificial heart. Expert Review of Medical Devices 2016;13(2):191-201. doi:10.1586/17434440.2016.1136212. https://pubmed.ncbi.nlm.nih.gov/26732059/
  18. Yaung J, Arabia FA, Nurok M. Perioperative care of the patient with the total artificial heart. Anesthesia and Analgesia 2017;124(5):1412-1422. doi:10.1213/ANE.0000000000001851. https://pubmed.ncbi.nlm.nih.gov/28107271/
  19. Rubin G, Colón MJ, Mahar J, Sunkara A, Yenigalla S, Arabía FA. A device profile of the SynCardia temporary total artificial heart as a bridge-to-transplantation in patients with biventricular failure. Expert Review of Medical Devices 2026;23(1):5-13. doi:10.1080/17434440.2025.2606884. https://pubmed.ncbi.nlm.nih.gov/41431108/
  20. Fuchs TK, Kadio B. Why total artificial hearts fail: hemocompatibility, infection, and the biological limits of durable cardiac replacement. Cureus 2026;18(3):e105988. doi:10.7759/cureus.105988. https://pubmed.ncbi.nlm.nih.gov/42046585/
  21. Poitier B, Chocron R, Peronino C, Philippe A, Pya Y, Rivet N, Richez U, Bekbossynova M, Gendron N, Grimmé M, Bories MC, Brichet J, Capel A, Rancic J, Vedie B, Roussel JC, Jannot AS, Jansen P, Carpentier A, Ivak P, Latremouille C, Netuka I, Smadja DM. Bioprosthetic total artificial heart in autoregulated mode is biologically hemocompatible: insights for multimers of von Willebrand factor. Arteriosclerosis, Thrombosis, and Vascular Biology 2022;42(4):470-480. doi:10.1161/ATVBAHA.121.316833. https://pubmed.ncbi.nlm.nih.gov/35139659/